Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Vienna, Austria, shares his immunotherapy highlights from this year’s IMS meeting, as well as unanswered questions regarding the use of these agents. Several questions remain in this space, including how to best sequence and combine these agents, how to improve immune responses in patients, and how to improve the efficacy of CAR-T cells. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.